INVITES BIOCORE CO. LTD
KKRX:2164001,369.00
KRW
+9.00
(+0.66%)
ISIN
KR7216400002
Return %
Stock
S&P 500
1Y
-62.80
14.20
3Y
-85.50
81.12
5Y
-86.96
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 133
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seoul South Korea
- IPO Date
- Jun 29, 2015
- Website
- bio-core.com
- Similar Companies
- Business
- Invites Biocore Co., Ltd. is a South Korea-based biotechnology and clinical contract research organization (CRO) that specializes in bioanalytical services, clinical trial management, genomic analysis, and molecular in vitro diagnostics. Founded in 2001 and headquartered in Seoul, South Korea, the company operates primarily through two core business segments: the Clinical CRO & Bioanalysis Division and the Genomics & In Vitro Diagnostics (IVD) Division. Through its Clinical CRO & Bioanalysis segment, the company provides comprehensive clinical development solutions including early-phase clinical study design; bioequivalence (BE) testing; Phase I through Phase IV clinical trial management; regulatory affairs consulting; clinical data management; biostatistical analysis; and high-throughput bioanalysis utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS) for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) evaluation of small molecules, biologics, peptide therapeutics, and advanced therapeutic modalities. Through its Genomics & IVD segment, the company develops, manufactures, and markets molecular diagnostic kits and genomic testing services, including real-time polymerase chain reaction (RT-PCR) kits for human papillomavirus (HPV) genotyping, respiratory pathogens, and sexually transmitted infections; next-generation sequencing (NGS) and microarray-based genetic profiling; non-invasive prenatal testing (NIPT); cancer genomic panels; hereditary disease screening; and pharmacogenomic testing. The company serves pharmaceutical manufacturers, biotechnology companies, clinical laboratories, hospitals, and academic research institutions across South Korea and international markets. In recent developments, the company rebranded from Biocore Co., Ltd. to Invites Biocore Co., Ltd. to reflect its strategic integration into the Invites Ecosystem consortium alongside affiliates including Invites Healthcare and Invites Genomics. Under this strategic reorganization, Invites Biocore has expanded its bioanalytical portfolio to support emerging drug modalities such as antibody-drug conjugates (ADCs) and cell and gene therapies, while entering strategic collaborations with academic medical institutions and digital health partners to establish integrated multi-omics genomic data platforms and advance personalized precision medicine capabilities.